$AVCO News

Last published 4y ago

4y agoAVCOAvalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"GlobeNewswireCompany to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) --
4y agoAVCOAvalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 MillionGlobeNewswireCompany to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests
4y agoAVCOAvalon GloboCare Receives Allowance for Joint U.S. PatentGlobeNewswireFREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company's intellectual property portfolio
4y agoAVCOAvalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical SocietyGlobeNewswireFindings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents related to QTY code applications jointly with MIT FREEHO
4y agoAVCOAvalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against CancerGlobeNewswireFREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protei
4y agoAVCOAvalon GloboCare to Present at the Jefferies 2022 Healthcare ConferenceGlobeNewswireFREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer
4y agoAVCOAvalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular TherapyGlobeNewswireGoal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in pre
4y agoAVCOAvalon GloboCare Expands IP Portfolio; Files 16 New Patent ApplicationsGlobeNewswireCo-inventors are leading international universities and cellular therapy developers Patent applications cover three types of cellular therapies and related technologies FREEHOLD, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp
4y agoAVCOAvalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell TherapiesGlobeNewswireLeveraging Avalon's existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeutics Clinical development of CAR-NK cell therapy planned in collaboration with the Company's clinical partner, Lu Daopei Hospital
4y agoAVCOAvalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical ProgramsGlobeNewswireCompany continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance FREEHOLD, N.J., Jan.
4y agoAVCOAvalon GloboCare's Chairman Converts Debt into Common Stock at 45% Premium to MarketGlobeNewswireFREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company's Chairman, Daniel Lu, has conver
4y agoAVCOAvalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy DevelopmentGlobeNewswireAvalon and research partner, Massachusetts Institute of Technology (MIT), combine their protein design "QTY Code" technology with Google's DeepMind artificial intelligence (AI) program, AlphaFold2, to accurately predict the 3D structures of protein rece
5y agoAVCOAvalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular ImmunotherapyGlobeNewswireCo-developed novel technology platform combining S-layer proteins and emulsomes for diverse applications in bio-delivery of drugs and genes with the University of Natural Resources and Life Sciences (BOKU) Vienna FREEHOLD, N.J., Oct. 14, 2021 (GLO
5y agoAVCOAvalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related DiseasesGlobeNewswireAvalon and research partner, University of Natural Resources and Life Sciences (BOKU), in Vienna, Austria, co-develop a novel technology to efficiently synthesize and study previously difficult to work with drug targets Technology will facilitate drug
5y agoAVCOAvalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30thGlobeNewswireFREEHOLD, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Benzinga
5y agoADIL AVCO SYSXSysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of DirectorsGlobeNewswireHERNDON, Va., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sysorex (OTCQB:SYSX) ("Sysorex" or the "Company"), the preeminent, U.S.-based, publicly traded Ethereum mining and technologies company, today announced that it has elected William B. Stilley, III to the
5y agoAVCOUPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCareGlobeNewswirePITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ:AVCO) aims to develop new cancer immunotherapy ap
5y agoABML AVCO DMPWW EPWCF+9Proactive news headlines including AEX Gold, Helix BioPharma, Imagine AR, Empower Clinics and Kintara TherapeuticsGlobeNewswireNew York , July 01, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Exactus Inc (OTCQB:EXDI) buys Colorado hemp produc
5y agoAVCOAvalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain CancerGlobeNewswireTrial evaluating EphA2-targeted CAR T-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option Anti-EphA2 CAR-T therapy appears to be well-tolerated thus far, based on initial safet
5y agoAVCO BIOC BUSXF CLGUF+13Proactive news headlines including The Parent Company, Phunware, Plurilock Security and Hannan MetalsGlobeNewswireNew York, June 28, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Vicinity Motor Corp (CVE:VMC) (OTCQX:BUSXF) (FRA:6LG)
5y agoAVCOAvalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBioGlobeNewswirePreviously Announced Execution of Definitive Agreement to Acquire SenlangBio SenlangBio Generated Revenue of USD $1.2 Million for the Three Months Ended March 31, 2021 and Projects $5 Million to $7 Million in Revenue for the Full Year 2021 USD $30
5y agoANTCF AREC ASWRF AVCO+15Proactive news headlines including Arizona Silver Exploration, Newrange Gold, Karora Resources, Ready Set Gold and AIM ImmunoTechGlobeNewswireNew York, June 14, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies Major Precious Metals Corp (CSE:SIZE) (OTC:SIZYF) (FRA:3EZ
5y agoAVCOAvalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock TransactionGlobeNewswireSenlangBio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal ("off-the-shelf") CAR-T and CAR-γδT cell therapy candidates targeting hematologic malignancies and solid tumors SenlangBio's l
5y agoAVCOAvalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021GlobeNewswireFREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Noble Capi
5y agoAVCO BLONF BNVIF CLGPF+16Proactive news headlines including Marvel Discovery, Tocvan Ventures, Altamira Gold, Water Tower Research and Clean Seed CapitalGlobeNewswireNew York , June 08, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Northstar Gold Corp (CSE:NSG) (OTC:NSGCF) (FRA:3WV
5y agoAVCOAvalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell SummitGlobeNewswireFREEHOLD, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces that the company's President and Chief Execu
5y agoAVCOAvalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR™ PlatformGlobeNewswireDevelopment of FLASH-CAR™ RNA-based cellular therapies includes utilization of Avalon’s new Point-of-Care Modular Autonomous Processing System (PMAPsys™)First FLASH-CAR™ candidate, AVA-011, on-track...
5y agoAVCOAvalon GloboCare Expands Co-Development Program with MIT to Combat Cancer MetastasisGlobeNewswireDual cutting edge technology approach using CRISPR-based genome editing and QTY code-based truncated chemokine receptors Expansion of co-development program with Dr. Shuguang Zhang at the...
5y agoAVCOAvalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular TherapeuticsGlobeNewswireAiming to accelerate the clinical development of S-layer nanotechnology for mucosal vaccines, hemo-filtration devices, cell-based therapies and other medical applicationsEstablishing state-of-the-art...
6y agoAVCOAvalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test DevicesGlobeNewswireFREEHOLD, N.J. and CHARLOTTESVILLE, Va., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (“Avalon”), a clinical-stage, global developer of cell-based technologies and...
6y agoADIL AVCOAvalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test DevicesACCESS NewswireAssure/Fastep® COVID-19 Point-of-Care Antibody Test is the First Test Granted FDA Emergency Use Authorization for Use with Fingerstick Blood Samples
6y agoAVCOAvalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical TrialGlobeNewswireExpanded AVA-001 CAR T-cell therapy clinical trial to include enrollment of patients with relapsed/refractory non-Hodgkin lymphomaCompleted pre-clinical study and standardized process development for...
6y agoAIM AVCO HTBX ORGSAIM ImmunoTech CEO to Participate in Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' on Thursday, September 10thACCESS NewswireAIM ImmunoTech Inc. (NYSE American:AIM), today announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET.
6y agoAVCOAvalon GloboCare CEO to Participate in Virtual Panel: “New Approaches to COVID-19: Hidden Breakthroughs,” on Thursday, September 10thGlobeNewswireFREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
6y agoAVCOAvalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)GlobeNewswireProgressing planned pre-clinical testing for innovative allogeneic MSC-based cellular therapy for both COVID-19 and aGVHD FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp....
6y agoAVCOAvalon GloboCare Announces Commercialization and Distribution Agreement with Cellex for COVID-19 Antibody Rapid Test KitGlobeNewswireFREEHOLD, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
6y agoAVCOAvalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine StormsGlobeNewswireExpands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on...
6y agoAVCOAvalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19GlobeNewswireCompleted Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or...
6y agoAVCOAvalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001GlobeNewswire- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity...
6y agoAVCOAvalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine CandidateGlobeNewswire- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel...
6y agoAVCOAvalon GloboCare Announces Three-Way Material Transfer Agreement with Weill Cornell Medicine and Arbele Limited for Development of Next Generation Cellular Immunotherapy FLASH-CAR™ TechnologyGlobeNewswireFREEHOLD, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that it has...
6y agoAVCOAvalon GloboCare Announces Diagnostic Platform for Point-of-Care Rapid Detection of COVID-19 (SARS-CoV-2) and Its Clinically Relevant Mutation StrainsGlobeNewswireEntered Into Strategic Partnership with GensKey Medical Technology Co. Ltd. to Co-Develop and Commercialize Point-of-Care Antibody-Based IgG/IgM and PCR-Based SARS-CoV-2 Detection Systems, Both of...
6y agoAVCOAvalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood CancersGlobeNewswireRNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of Viral VectorsCapable of...
6y agoAVCOAvalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX™ Product Development and CommercializationGlobeNewswireFocused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product DevelopmentSigned Three-Way Material Transfer Agreement between Avalon GloboCare,...
6y agoAVCOAvalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and MortalityGlobeNewswireCompleted Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as “Molecular Mop” to Remove Excessive Cytokines (“Cytokine Storm”) Related to Coronavirus Infection and Cellular...
6y agoAVCOAvalon GloboCare to Present at Biotech Showcase™ 2020GlobeNewswireFREEHOLD, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today announced its Chief...
6y agoAVCOAvalon GloboCare Partners with China (Nanjing) Cell Valley to Advance Cellular MedicinesGlobeNewswireForms Major Regional Hub in China for CellTech IndustryPartnership Delivers Synergy of Infrastructural Resources for Clinical Development and Bioprocessing Technologies in Cellular Therapy ...
7y agoAVCOAvalon GloboCare Announces Initiation of First-in-Human Clinical Trial of its CAR-T Candidate, AVA-001, for Treatment of B-Cell MalignanciesGlobeNewswireFREEHOLD, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has initiated its...
7y agoAVCOAvalon GloboCare Expected to Join the Russell 3000® IndexPR NewswireAvalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that it expects to be...
7y agoAVCOAvalon GloboCare President and CEO David Jin, M.D., Ph.D. to Chair the "Research and Application of Stem Cell Exosomes" Session at This Year's Second International Aesthetic Industry ConferencePR NewswireAvalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the Company's...